Company Overview of ZymoGenetics Inc.
ZymoGenetics Inc., a biopharmaceutical company, develops and commercializes therapeutic proteins for the treatment of human diseases. It provides RECOTHROM Thrombin, a topical recombinant in the United States; PEG-Interferon lambda for treatment of hepatitis C virus infection; IL-21 for treatment of metastatic melanoma; and anti-IL-31 monoclonal antibody for treatment of atopic dermatitis. ZymoGenetics Inc. was formerly known as Zymos and changed its name to ZymoGenetics Inc. in 1983. The company was founded in 1981 and is headquartered in Seattle, Washington. As of October 7, 2010, ZymoGenetics Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
1201 Eastlake Avenue East
Seattle, WA 98109
Founded in 1981
Key Executives for ZymoGenetics Inc.
Similar Private Companies By Industry
|SanBio, Inc.||United States|
|Van Andel Institute||United States|
|Puronyx, Inc.||United States|
|Upstate USA, Inc.||United States|
|United Medical Industrial Group, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- Summit, NJ | DiversantPosted: Jul 03
- Fort Lauderdale, FL | Broward HealthPosted: Dec 16
- Brown Deer, WI | Kelly Scientific ResourcesPosted: Dec 13
- New York, LA | KjmPosted: Dec 19
Sponsored Financial Commentaries
To contact ZymoGenetics Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.